Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1

Conditions

Leukemia, Myeloid, Acute 3Sarcoma 2Recurrence 2Uterine Cervical Neoplasms 1Testicular Germ Cell Tumor 1Stomach Neoplasms 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Neoplasms 1Myelodysplastic Syndromes 1Melanoma 1Lymphoma 1Liposarcoma 1Cholangiocarcinoma 1Carcinoma, Non-Small-Cell Lung 1Biliary Tract Neoplasms 1Adrenocortical Carcinoma 1Adenocarcinoma of Lung 1

Interventions

fludarabine phosphate 87Cyclophosphamide 78Whole-Body Irradiation 59Azacitidine 59fludarabine 56Mycophenolic Acid 56Busulfan 53Tacrolimus 51Peripheral Blood Stem Cell Transplantation 41Melphalan 40Cytarabine 38Antilymphocyte Serum 38Filgrastim 37Granulocyte Colony-Stimulating Factor 33Cyclosporine 33Methotrexate 32Decitabine 32thymoglobulin 22Thiotepa 21Clofarabine 21Cord Blood Stem Cell Transplantation 19Stem Cell Transplantation 16Alemtuzumab 16Sirolimus 15Rituximab 15sargramostim 12Lenalidomide 12Etoposide 11Radiotherapy 10Cyclosporins 10

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Myelodysplastic Syndromes × milademetan × Clear all
NCT02319369 2021-10-11

Safety, Tolerability and Pharmacokinetics of Milademetan Alone and With 5-Azacitidine (AZA) in Acute Myelogenous Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS)

Daiichi Sankyo

Phase 1 Terminated
74 enrolled 30 charts
MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Recurrence, Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡